TY - JOUR
T1 - Thyroid dysfunction in children with leukemia over the first year after hematopoietic stem cell transplantation
AU - Lee, Yoon Ji
AU - Lee, Hyun Young
AU - Ahn, Moon Bae
AU - Kim, Seong Koo
AU - Cho, Won Kyoung
AU - Lee, Jae Wook
AU - Chung, Nack Gyun
AU - Cho, Bin
AU - Suh, Byung Kyu
N1 - Publisher Copyright:
© 2018 2018 Walter de Gruyter GmbH, Berlin/Boston.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Thyroid function in children with leukemia during the first year after hematopoietic stem cell transplantation (HSCT) was investigated. The medical records of 186 subjects [111 boys and 75 girls; lymphoid=75, myeloid=111; median age at HSCT was 10.7 (0.8-21.8) years old] were reviewed retrospectively. In children with leukemia, T3 decreased at 1 month (p<0.001) and recovered 9 months to the levels before HSCT. TSH decreased at 1 month (p<0.001), recovered at 3 months and increased at 12 months (p<0.001) to the levels before HSCT. The incidence of euthyroid sick syndrome (ESS, 23.2%, 15.5%, 5.9%, 5.2%, 3.9%, p for trend <0.001) decreased and subclinical hypothyroidism (SH, 0%, 3.9%, 14.8%, 22.1%, 21.3%, p for trend <0.001) increased at 1, 3, 6, 9 and 12 months after HSCT. Out of 55 patients developing ESS during 3 months after HSCT, 54 recovered to normal thyroid function within 5 months without medication. Among the total 186 subjects, 21 patients have been treated with levothyroxine. Both height and weight standard deviation scores continued to decrease over 1 year after HSCT. In children with leukemia, one-quarter had ESS at 1 month and one-fifth had SH at 12 months and continued growth impairments were observed during 1 year after HSCT. Most of the ESS patients recovered to normal within 5 months without medication. More long-term follow-up of thyroid function and growth in children with leukemia after HSCT is crucial.
AB - Thyroid function in children with leukemia during the first year after hematopoietic stem cell transplantation (HSCT) was investigated. The medical records of 186 subjects [111 boys and 75 girls; lymphoid=75, myeloid=111; median age at HSCT was 10.7 (0.8-21.8) years old] were reviewed retrospectively. In children with leukemia, T3 decreased at 1 month (p<0.001) and recovered 9 months to the levels before HSCT. TSH decreased at 1 month (p<0.001), recovered at 3 months and increased at 12 months (p<0.001) to the levels before HSCT. The incidence of euthyroid sick syndrome (ESS, 23.2%, 15.5%, 5.9%, 5.2%, 3.9%, p for trend <0.001) decreased and subclinical hypothyroidism (SH, 0%, 3.9%, 14.8%, 22.1%, 21.3%, p for trend <0.001) increased at 1, 3, 6, 9 and 12 months after HSCT. Out of 55 patients developing ESS during 3 months after HSCT, 54 recovered to normal thyroid function within 5 months without medication. Among the total 186 subjects, 21 patients have been treated with levothyroxine. Both height and weight standard deviation scores continued to decrease over 1 year after HSCT. In children with leukemia, one-quarter had ESS at 1 month and one-fifth had SH at 12 months and continued growth impairments were observed during 1 year after HSCT. Most of the ESS patients recovered to normal within 5 months without medication. More long-term follow-up of thyroid function and growth in children with leukemia after HSCT is crucial.
KW - children
KW - growth
KW - hematopoietic stem cell transplantation
KW - leukemia
KW - thyroid
UR - http://www.scopus.com/inward/record.url?scp=85055539454&partnerID=8YFLogxK
U2 - 10.1515/jpem-2018-0162
DO - 10.1515/jpem-2018-0162
M3 - Article
C2 - 30325734
AN - SCOPUS:85055539454
SN - 0334-018X
VL - 31
SP - 1241
EP - 1247
JO - Journal of Pediatric Endocrinology and Metabolism
JF - Journal of Pediatric Endocrinology and Metabolism
IS - 11
ER -